Literature DB >> 50161

The value of combined 5-fluorouracil and x-ray therapy in the palliation of locally recurrent and inoperable rectal carcinoma.

S J Arnott.   

Abstract

The difficulties of treating patients with pelvic recurrence from rectal cancer by further suegery, chemotherapy or by radiotherapy are summarised. Fifty-fibe patients with this form of recurrence are presented to whom 5-fluouracil was administered to improve the effectiveness of radiotherapy. A safe and effective regime is described which produced complete relief of pain in 66 percent of the patients who presented with this symptom with a further 16 percent obtaining partial relief. Total resolution of tumour masses and complete relief from mucoid rectal discharge were achieved less often, although the majority of patients derived benefit from treatment. An important finding of this study has been that in this particular group of patients a short, low-dose course of combined therapy was as effective, both in the relief of symptoms and the prolongation of survival, as more prolonged high-dose treatment.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 50161      PMCID: PMC8332541          DOI: 10.1016/s0009-9260(75)80037-7

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  4 in total

Review 1.  Locally Advanced Disease and Pelvic Exenterations.

Authors:  Christos Kontovounisios; Paris Tekkis
Journal:  Clin Colon Rectal Surg       Date:  2017-12-01

Review 2.  Progress report. Cytotoxic therapy for gastrointestinal carcinoma.

Authors:  T J Prostman
Journal:  Gut       Date:  1976-04       Impact factor: 23.059

3.  Conservative treatment of anorectal tumors.

Authors:  J Kovarik; V H Svoboda; B Higgins
Journal:  Strahlenther Onkol       Date:  1998-08       Impact factor: 3.621

4.  Recent advances in cytotoxic therapy for gastrointestinal carcinoma: a review.

Authors:  T J Priestman
Journal:  J R Soc Med       Date:  1978-03       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.